Summit Therapeutics Inc. Increase Decrease Through Cumulative Catchup Adjustments To Revenue Contract Liabilities
Summit Therapeutics Inc. (SMMT) reported Increase Decrease Through Cumulative Catchup Adjustments To Revenue Contract Liabilities of GBP 10.58 million for the 12-month period ending 2018-01-31, per its 20-F filed 2019-03-29.
Discontinued › Income Statement › Other Income
ifrs-full:IncreaseDecreaseThroughCumulativeCatchupAdjustmentsToRevenueContractLiabilities · last filed 2019-03-29
- Summit Therapeutics Inc. increase decrease through cumulative catchup adjustments to revenue contract liabilities for the quarter ending 2018-01-31 was 2.47M GBP.
| Period end | Increase Decrease Through Cumulative Catchup Adjustments To Revenue Contract Liabilities 3 month | Increase Decrease Through Cumulative Catchup Adjustments To Revenue Contract Liabilities 9 month | Increase Decrease Through Cumulative Catchup Adjustments To Revenue Contract Liabilities 12 month |
|---|---|---|---|
| 2018-01-31 | 2.47M GBP derived: 20-F 12 month − 6-K 9 month · filed 2019-03-29 | 10.58M GBP 20-F · filed 2019-03-29 | |
| 2017-10-31 | 8.11M GBP 6-K · filed 2018-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |